Biotechnology company: Flex Pharma, Flex Pharma, Inc. (FLKS)

Flex Pharma Flex Pharma, Inc. (NASDAQ:FLKS) was founded in 2014 and is headquartered in Boston, Massachusetts, USA, with 20 full-time employees. It is a biotechnology company that develops and commercializes treatments related to neurological diseases and sports in the US The product of muscle cramps, twitches and cramps.

Flex Pharma

Flex Pharma, Flex Pharma, Inc. (FLKS):

Flex Pharmaceuticals is divided into two parts of operation : Consumer Operations and Drug Development.

Flex Pharma’s main drug candidate is FLX-787, a chemically synthesized single molecule and double transient receptor potential V1/A1 ion channel activator, which is undergoing exploratory phase II clinical trials in Australia for the treatment of multiple sclerosis Patients; and two phase II clinical trials in the United States for the treatment of motor neuron disease in amyotrophic lateral sclerosis.

Flex Pharma also offers HOTSHOT, a consumer beverage used to prevent and treat exercise-related muscle cramps. The company sells and sells its HOTSHOT products online through its e-commerce website and specialty retailers.

Notify of
Inline Feedbacks
View all Intels

Anticancer drug company: Loxo Oncology (LOXO) (2013)

FDA clinical trial process-how long does it take for a new drug to be marketed in the United States?